Ge‐Liang Xu

1.8k total citations
62 papers, 1.3k citations indexed

About

Ge‐Liang Xu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Ge‐Liang Xu has authored 62 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 20 papers in Cancer Research and 17 papers in Oncology. Recurrent topics in Ge‐Liang Xu's work include Cancer, Hypoxia, and Metabolism (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers) and Peptidase Inhibition and Analysis (7 papers). Ge‐Liang Xu is often cited by papers focused on Cancer, Hypoxia, and Metabolism (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers) and Peptidase Inhibition and Analysis (7 papers). Ge‐Liang Xu collaborates with scholars based in China and Egypt. Ge‐Liang Xu's co-authors include Weidong Jia, Yongsheng Ge, Jinliang Ma, Ji-Hai Yu, Weihua Ren, Jiansheng Li, Chuanhai Zhang, Wenbin Liu, Jiansheng Li and Xiaojie Sun and has published in prestigious journals such as Nature Communications, PLoS ONE and Scientific Reports.

In The Last Decade

Ge‐Liang Xu

61 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ge‐Liang Xu China 23 661 359 354 216 215 62 1.3k
Weihua Ren China 20 661 1.0× 258 0.7× 409 1.2× 160 0.7× 93 0.4× 43 1.1k
Michelle Chaisson United States 10 660 1.0× 309 0.9× 330 0.9× 229 1.1× 249 1.2× 12 1.3k
Jack Leslie United Kingdom 17 396 0.6× 184 0.5× 208 0.6× 260 1.2× 203 0.9× 34 1.1k
Nan You China 19 656 1.0× 250 0.7× 410 1.2× 172 0.8× 212 1.0× 61 1.3k
Bai Ruan China 22 782 1.2× 195 0.5× 567 1.6× 295 1.4× 250 1.2× 33 1.3k
Usman Yaqoob United States 19 717 1.1× 238 0.7× 278 0.8× 430 2.0× 456 2.1× 29 1.4k
Wenfang Tian China 17 588 0.9× 247 0.7× 152 0.4× 232 1.1× 138 0.6× 34 1.1k
Jianwen Cheng China 21 674 1.0× 409 1.1× 279 0.8× 115 0.5× 152 0.7× 53 1.2k

Countries citing papers authored by Ge‐Liang Xu

Since Specialization
Citations

This map shows the geographic impact of Ge‐Liang Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ge‐Liang Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ge‐Liang Xu more than expected).

Fields of papers citing papers by Ge‐Liang Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ge‐Liang Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ge‐Liang Xu. The network helps show where Ge‐Liang Xu may publish in the future.

Co-authorship network of co-authors of Ge‐Liang Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Ge‐Liang Xu. A scholar is included among the top collaborators of Ge‐Liang Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ge‐Liang Xu. Ge‐Liang Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sheng, Zhi-yong, Xiaolin Wang, Ge‐Liang Xu, Ge Shan, & Liang Chen. (2019). Analyses of a Panel of Transcripts Identified From a Small Sample Size and Construction of RNA Networks in Hepatocellular Carcinoma. Frontiers in Genetics. 10. 431–431. 18 indexed citations
2.
3.
Pan, Tingting, Wei Wang, Weidong Jia, & Ge‐Liang Xu. (2017). A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. Oncology Letters. 13(5). 2957–2964. 18 indexed citations
4.
Xu, Ge‐Liang, Zhiyong Sheng, Yang Lv, et al.. (2016). Expression and clinical significance of Nectin-4 in hepatocellular carcinoma. OncoTargets and Therapy. 9. 183–183. 29 indexed citations
5.
Jia, Weidong, et al.. (2015). Clinical pathway of enhanced recovery after surgery in patients undergoing hepatectomy for primary liver cancer. Zhonghua putong waike zazhi. 30(11). 862–865. 2 indexed citations
6.
Pan, Jingjing, Dong Liu, Ge‐Liang Xu, et al.. (2015). Expression of Kindlin-1 in human hepatocellular carcinoma and its prognostic significance. Tumor Biology. 36(6). 4235–4241. 12 indexed citations
7.
Pan, Jingjing, Yongsheng Ge, Ge‐Liang Xu, et al.. (2013). The expression of YKL-40 in hepatocellular carcinoma and its clinical significance. Zhonghua gan-dan waike zazhi. 19(6). 433–437.
8.
Lv, Yang, Weidong Jia, Qikai Sun, et al.. (2012). High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma. Medical Oncology. 30(1). 385–385. 42 indexed citations
9.
Xu, Ge‐Liang. (2011). STRUCTURED TRIGLYCERIDES WERE WELL TOLERATED AND INDUCED AFTER HEPATECTOMY IN PATIENTS WITH HEPATOCARCINOMA. 1 indexed citations
10.
Xu, Ge‐Liang. (2011). THE CLINICAL VALUE OF CONTRAST-ENHANCED ULTRASONOGRAPHY IN DIAGNOSING PRIMARY HEPATOCELLULAR CARCINOMA. 1 indexed citations
11.
Xu, Ge‐Liang, Weidong Jia, Yongsheng Ge, et al.. (2011). Prognostic significance of osteopontin in hepatocellular carcinoma: A meta‐analysis. International Journal of Cancer. 130(11). 2685–2692. 37 indexed citations
12.
Wang, Wei, Jinliang Ma, Weidong Jia, & Ge‐Liang Xu. (2011). Periostin: a putative mediator involved in tumour resistance to anti-angiogenic therapy?. Cell Biology International. 35(11). 1085–1088. 9 indexed citations
13.
Liu, Wenbin, Ge‐Liang Xu, Weidong Jia, et al.. (2010). Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma. Medical Oncology. 28(S1). 228–238. 71 indexed citations
14.
15.
Zhang, Chuanhai, Ge‐Liang Xu, Weidong Jia, et al.. (2010). Activation of STAT3 Signal Pathway Correlates with Twist and E-Cadherin Expression in Hepatocellular Carcinoma and Their Clinical Significance. Journal of Surgical Research. 174(1). 120–129. 48 indexed citations
16.
Chen, Hao, Weidong Jia, Jiansheng Li, et al.. (2010). Extracellular matrix protein 1, a novel prognostic factor, is associated with metastatic potential of hepatocellular carcinoma. Medical Oncology. 28(S1). 318–325. 33 indexed citations
17.
Huang, Qiang, et al.. (2009). Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis. Medical Oncology. 27(3). 867–875. 14 indexed citations
18.
19.
Wang, Wei, Weidong Jia, Ge‐Liang Xu, et al.. (2008). Antitumoral Activity of Rapamycin Mediated Through Inhibition of HIF-1alpha and VEGF in Hepatocellular Carcinoma. Digestive Diseases and Sciences. 54(10). 2128–2136. 27 indexed citations
20.
Wang, Jian, Qiong Xue, Weidong Jia, et al.. (2003). Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. Journal of Cancer Research and Clinical Oncology. 129(6). 327–334. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weihua Ren Breakdown of academic impact, for papers by Michelle Chaisson Breakdown of academic impact, for papers by Jack Leslie Breakdown of academic impact, for papers by Nan You Breakdown of academic impact, for papers by Bai Ruan Breakdown of academic impact, for papers by Usman Yaqoob Breakdown of academic impact, for papers by Wenfang Tian Breakdown of academic impact, for papers by Jianwen Cheng
Rankless by CCL
2026